Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacovigilance01:19

Pharmacovigilance

1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drug Nomenclature01:17

Drug Nomenclature

3.2K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
3.2K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

4.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
4.4K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

306
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
306
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

147
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
147
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

7.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Subtype-Specific Risk and Temporal Dynamics of Brain Metastases in Metastatic Breast Cancer.

Clinical breast cancer·2026
Same author

Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.

Genome biology·2026
Same author

Vitamin/mineral and non-vitamin/non-mineral supplement use of breast cancer survivors in Korea.

Nutrition research and practice·2026
Same author

Germline Mutations Related to Complete Remission After Neoadjuvant Chemotherapy in Patients With Triple-negative Breast Cancer.

Journal of breast cancer·2026
Same author

Clinicopathologic characteristics and lymph node status in the NAUTILUS clinical trial:KBCSG-21.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Performance of Repair Mortars Composed of Calcium Sulfoaluminate and Amorphous Calcium Aluminate.

Materials (Basel, Switzerland)·2026

関連する実験動画

Updated: Jan 15, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.3K

医薬品併用禁忌のための検索拡張大規模言語モデルシステム

Byeonghun Bang1, Jongsuk Yoon1, Dong-Jin Chang2

  • 1Department of Computer Engineering, Hongik University, Seoul, 04066 South Korea.

Health information science and systems
|January 14, 2026
PubMed
まとめ

本研究では、検索拡張生成(RAG)パイプラインを使用して、医薬品併用禁忌のための大規模言語モデル(LLM)を強化します。RAGアプローチは、薬剤相互作用の特定における精度を大幅に向上させ、より安全な投薬ガイダンスを保証します。

キーワード:
医薬品併用禁忌大規模言語モデル検索拡張生成

さらに関連する動画

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

1.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

関連する実験動画

Last Updated: Jan 15, 2026

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
05:47

Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems

Published on: June 13, 2025

1.3K
Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

1.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

科学分野:

  • 医療情報学
  • ヘルスケアにおける人工知能
  • 医薬品安全性監視

背景:

  • 大規模言語モデル(LLM)は汎用性を示しますが、特に医薬品併用禁忌のようなクリティカルなデータにおいては、ヘルスケア分野で課題に直面しています。
  • 医薬品併用禁忌に関する正確で信頼性の高い情報は、患者の安全と効果的なヘルスケアに不可欠です。
  • 既存のLLMアプリケーションは、薬剤相互作用や患者固有の警告のような複雑な医療情報を確実に処理するために強化が必要です。

研究 の 目的:

  • 医薬品併用禁忌を正確に特定するLLMの機能を強化すること。
  • 併用禁忌検出の改善のために、検索拡張生成(RAG)パイプラインを実装および評価すること。
  • 正確な併用禁忌情報を通じて、処方および薬剤摂取決定における不確実性を削減すること。

主な方法:

  • OpenAIのGPT-4o-miniをベースLLMとして、text-embedding-3-smallを埋め込みに使用しました。
  • LangChainフレームワークを使用して、再ランキング付きのハイブリッド検索システムを統合しました。
  • 年齢、妊娠、併用薬に関する併用禁忌に焦点を当てた薬剤使用レビュー(DUR)データを利用しました。

主要な成果:

  • ベースラインLLMの併用禁忌に関する精度は0.49から0.57の範囲でした。
  • RAGパイプラインは、精度を年齢で0.94、妊娠で0.87、併用薬で0.89に大幅に向上させました。
  • 処方および薬剤摂取決定における不確実性を大幅に削減しました。

結論:

  • RAGフレームワークでLLMを拡張することにより、医薬品併用禁忌情報の精度が大幅に向上します。
  • 開発されたRAGパイプラインは、信頼性の高い薬剤安全性情報検索のための有望なソリューションを提供します。
  • このアプローチは、投薬管理における臨床的意思決定と患者の安全性を向上させることができます。